Stephanie Halene MD
Professor, Hematology, Comprehensive Cancer Center, Yale University School of Medicine
Join to view full profile
Park St.New Haven, CT 06520
Phone+1 203-200-4363
Dr. Halene is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2002 - 2006
Eberhard Karls University Faculty of MedicineClass of 1993
Certifications & Licensure
CT State Medical License 2006 - 2027
American Board of Internal Medicine Hematology
Publications & Presentations
PubMed
- A spatial multi-omics atlas of immunosenescence reveals germinal-center B cell dysfunction in human lymph nodes.Negin Farzad, Archibald Enninful, Yao Lu, Fabio Parisi, Anthony Fung
Cell Press Blue. 2026-07-20 - Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).Giulia Maggioni, Gabriele Todisco, Elisabetta Sauta, Luca Lanino, Somedeb Ball
Hemasphere. 2026-06-01 - Real-world investigation of platelet apoptosis for mechanistic insights into severe immune thrombocytopenia and bleeding.Tarun Tyagi, Kanika Jain, Martin Matthews, Stephanie Halene, John Hwa
Research and Practice in Thrombosis and Haemostasis. 2026-05-01
Journal Articles
- SRSF2 Mutations Drive Oncogenesis by Activating a Global Program of Aberrant Alternative Splicing in Hematopoietic CellsRadovan Vasic, Stephanie Halene, Nature
Abstracts/Posters
- Variable Response to BCL2 Inhibition in MDS Is Enhanced across MDS Subtypes with Synergistic Combination of BCL2+MCL1 InhibitionStephanie Halene, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center ExperienceStephanie Halene, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- LAM-003, a Novel Oral Heat Shock Protein 90 Inhibitor for Treatment of Acute Myeloid Leukemia, Including Wild-Type and FMS-like Tyrosine Kinase 3 (FLT3)-Mutant DiseaseStephanie Halene, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Listen to, "How Can Artificial Intelligence Advance Medical Education and Research to Transform Patient Care?"June 11th, 2024- New Yale Study Shows Potential Target for Treating Blood CancersMarch 31st, 2022
- Tissue Mapping Center for Cellular Senescence Launched at Yale Cancer Center to Study Human Lymphoid OrgansOctober 20th, 2021
Grant Support
- Center for Human Lymphoma Spatiotemporal Atlas (HuLymSTA)YALE UNIVERSITY2024–2029
- Targeting Defective DNA Damage Response Pathways in IDH1/2-mutant AMLYALE UNIVERSITY2022–2027
- Targeting Defective DNA Damage Response Pathways in IDH1/2-mutant AMLYALE UNIVERSITY2022–2027
- Pan-Organ Spatial Atlas of Immunosenescence: Decoding Immune Aging Across Tissues and ScalesYALE UNIVERSITY2021–2026
- Pan-Organ Spatial Atlas of Immunosenescence: Decoding Immune Aging Across Tissues and ScalesYALE UNIVERSITY2021–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
